Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Date:10/30/2008

- Conference Call Today at 5 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the third quarter ended September 30, 2008.

"During the quarter we continued to make important progress in developing picoplatin as an oncology platform compound, addressing multiple indications, combinations and formulations. Last week, we presented positive updated Phase 2 data with picoplatin in colorectal cancer (CRC) and hormone-refractory prostate cancer (HRPC) at the EORTC oncology symposium in Geneva. In addition, our ongoing Phase 3 trial with picoplatin in lung cancer (SCLC) is on track to advance picoplatin toward commercialization in 2010," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "These ongoing clinical trials are generating data that support the development of picoplatin for broad use in overcoming platinum resistance, reducing side effects such as neurotoxicities seen with other platinum therapies, and as an agent in novel combination therapies. In the third quarter, we also secured a $27.6 million amended loan facility, which strengthens our financial position and allows us to operate our business into 2010 and prepare picoplatin for commercialization."

Third Quarter and Recent Highlights

Picoplatin Clinical Development

-- Presented updated results from our ongoing randomized, Phase 2 trial of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) in patients with metastatic CRC this month at the 20th EORTC-NCI-AACR oncology symposium. Results showed that picoplatin, given once eve
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...Finding and treating a tumor without disturbing no...t effective therapies can be invasive and harsh. ,...ave devised a way they might deliver the right the...alled aptamers, which specifically bind to living ...tamers in a rodent with liver cancer until they fo...
(Date:11/30/2009)... According to Steven McConnell, DDS, teac...ng flu season is a good idea, but brushing their t...ally coming down with a virus. , ...the California Dental Hygienists’ Associatio...ween oral health and flu prevention because the H1...
(Date:11/30/2009)...AGO, Nov. 30 Three decades ago, a ...ing swallowed by children, prompting a switch by U...ted today at the annual meeting of the Radiologica...ew tabs are still potentially unsafe. ,, "One o...ge can construction in the U.S. was to eliminate i...
(Date:11/30/2009)... decades ago, a study revealed that beverage can p...ng a switch by U.S. manufacturers to stay-tabs. Bu... the Radiological Society of North America (RSNA) ...fe. , "One of the driving factors leading the ch...to eliminate inadvertent swallowing of the pull-ta...
(Date:11/29/2009)... Moravia,s Nanjing-based Service Delivery...e , Brno, Czech Republic ...ion solution provider, is pleased to announce its ...2009, to be held in Nanjing, China, on November 30...nion-based companies that have established and gro...
Breaking Medicine News(10 mins):Health News:First live targeting of tumors with RNA-based technology 2Health News:First live targeting of tumors with RNA-based technology 3Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 2Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 3Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 4Health News:Beverage Can Stay-Tabs Pose Swallowing Risk 2Health News:Beverage can stay-tabs pose swallowing risk 2Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2
...previously noted low rates of successful hepatitis... large part due to very early differences in the a...y is published in the April 15 issue of the Journ...f the population is infected. Chronic HCV infectio...
...ups, survival odds after angioplasty are not as gr...-- A major international study pinpoints which peo...ter off having bypass surgery than artery-opening ...cy and cardiovascular medicine at Stanford Univers...
...ng Helps Mainstream Management Process , , STUART... Health Systems, a not-for-profit, community-based...Florida, needed a way to track potential conflicts...ncommon for outside interests and business prospec...
...ta Barbara, California, offshore oil spill gave bi... States a leader in environmental protection world...n a key issue to both industrial and environmental...ciety. , In his new book, The Conflict over Envi...
...e Savvy Self-Funding Healthcare Conference and Exp...the opportunity to discuss creative healthcare opt...City, Missouri. , , This unique conference is des...nt to help educate employers and plan sponsors on ...
...versity, together with colleagues at the Karolinsk...nd all the genes the determine the dosage of the b...ished in the scientific journal PLoS Genetics . ,...he two most important genes are among those we pre...
Other Medicine News:Health News:2-day results predict ultimate response to therapy in chronic hepatitis C 2Health News:Diabetics and Elderly May Fare Better With Bypass 2Health News:Diabetics and Elderly May Fare Better With Bypass 3Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 2Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 3Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 4Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 5Health News:An even-handed analysis of environmental policy 2Health News:Deffenbaugh Industries to Host Self-Funding Healthcare Conference in Kansas City 2
(Date:11/30/2009)..., , RICHMOND, Va., Nov. 30 /PRNewswire/ -...icense with sanofi-aventis U.S. for a novel epinep...ory. Under the license, sanofi-aventis U.S. shall ...tion. Intelliject will be responsible for the on-g... approval and has retained certain co-promotion ri...
(Date:11/30/2009)..., , ATLANTA, G...College of,Direct Support (CDS), an internet-based...anaged in partnership by MC Strategies/Elsevier an...ining Center, announced today that,its second Disa...is now,available for administrators and learners t...
(Date:11/29/2009)..., , CHICAGO, Nov. 30 Middl...physical activity may be unknowingly causing damag...eoarthritis, according to a study presented today ...of North America (RSNA). ,, "Our data suggest t...y be at greater risk for developing knee abnormali...
Breaking Medicine Technology:Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 2Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 3Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 2Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 3Too Much Physical Activity May Lead to Arthritis 2Too Much Physical Activity May Lead to Arthritis 3Female Supervisors More Likely to Be Sexually Harassed 54300 1Female Supervisors More Likely to Be Sexually Harassed 54300 2Female Supervisors More Likely to Be Sexually Harassed 54300 3September is Prostate Cancer Awareness Month 54295 1September is Prostate Cancer Awareness Month 54295 2Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 54292 1Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 54292 2
...il 29 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA... clinical trial of AZ-007 (Staccato(R) zaleplon). ...veloped for the treatment of insomnia,patients who...s who awake,in the middle of the night and have di... product candidate using our single-dose Staccato,...
...and multi-lesion clinical trial data to be pre..., May 13, MENLO PARK, Calif., April 28 XTENT, In...ts for the first quarter ended,March 31, 2008., T...r $0.54 per share,for the first quarter of 2008, c...r share, for the first quarter of 2007. The compan...
Other Medicine Technology:Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 2Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 3Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 4XTENT Announces First Quarter 2008 Financial Results 2XTENT Announces First Quarter 2008 Financial Results 3XTENT Announces First Quarter 2008 Financial Results 4XTENT Announces First Quarter 2008 Financial Results 5
Replacement Bulb: HBO 100W/2
Replacement Bulb: FCS
Replacement Bulb: ELH
Replacement Bulb: EJA
Medicine Products: